Technology
Health
Biotechnology
Arbutus Biopharma
$3.749876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.12 (-3.11%) Today
-$0.12 (-3.11%) Today
Why Robinhood?
You can buy or sell ABUS and other stocks, options, ETFs, and crypto commission-free!
About
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
Employees
80
Headquarters
Burnaby, British Columbia
Founded
2005
Market Cap
214.30M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
326.89K
High Today
$3.91
Low Today
$3.74
Open Price
$3.89
Volume
9.96K
52 Week High
$12.60
52 Week Low
$3.20
Collections
Technology
Health
Biotechnology
2015 IPO
Canada
North America
News
The Motley FoolMar 7
Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript
Arbutus Biopharma Corp (NASDAQ:ABUS) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Fourth Quarter and 2018 Year-End Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today's co...
Associated PressMar 7
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. - Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available RNA destabilizer, with a go/...
Simply Wall StMar 2
The Arbutus Biopharma Share Price Is Down 85% So Some Shareholders Are Rather Upset
Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders should be happy to see the share price up 18% in the last month. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 85%. The recent bounce might mean the long decline is over, but we are not confident. The fundamental business performance will ultimately determine if the turnaround can be sustained. We really feel for...
Price Paid on Robinhood
31% Lower
Right Now
52 Week Low
$3.20
Average Price Paid
$5.44
52 Week High
$12.60
Earnings
-$0.44
-$0.35
-$0.26
-$0.17
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
-$0.37 per share